MG
MGNX.US MacroGenics Inc
- Market cap
- USD 141M
- P/E
- -
- P/B
- 5.64x
- ROE
- -197.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MGNX.US undervalued?
Graham numberThe Graham number of MacroGenics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MacroGenics Inc fundamental analysis
No fundamental analysis for MacroGenics Inc yet.
MacroGenics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear…
Full company profileMacroGenics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MacroGenics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 86.6M | 156M | 60.1M | 62.0M | 97.8M | 75.6M | 152M | 57.2M | 148M | 150M | 96.4M |
| Gross Profit | 86.6M | 156M | 60.1M | 62.0M | 97.8M | 73.0M | 145M | 49.0M | 136M | 106M | -32.8M |
| Operating Income | -60.0M | -22.1M | -171M | -177M | -131M | -203M | -121M | -168M | -111M | -72.8M | -90.1M |
| EBITDA | -52.4M | -14.9M | -162M | -165M | -119M | -192M | -110M | 2.02M | -57.4M | -59.6M | -149M |
| Net Income | -58.5M | -19.6M | -171M | -152M | -118M | -191M | -120M | -9.06M | -67.0M | -74.6M | -49.8M |
| EPS | -1.69 | -0.54 | -4.19 | -3.16 | -2.25 | -3.18 | -1.95 | -0.15 | -1.07 | -1.18 | -0.78 |
| Balance Sheet | |||||||||||
| Total Assets | 311M | 374M | 332M | 313M | 379M | 335M | 290M | 298M | 262M | 257M | 319M |
| Total Liabilities | 42.5M | 74.6M | 89.3M | 81.9M | 82.9M | 95.6M | 147M | 146M | 146M | 201M | 294M |
| Shareholders' Equity | 269M | 299M | 243M | 231M | 296M | 240M | 142M | 153M | 116M | 55.6M | 25.2M |
| Cash & Short-term Investments | 277M | 305M | 233M | 216M | 273M | 244M | 154M | 230M | 202M | 190M | 288M |
| Total Debt | 1.89M | 298K | - | 30.6M | 29.2M | 25.5M | 34.8M | 34.0M | 37.5M | 107M | 34.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -43.7M | 14.4M | -153M | -134M | -112M | -144M | -87.0M | -78.2M | -68.4M | -81.0M | -111M |
| Capital Expenditure | 11.4M | 29.4M | 25.0M | 4.29M | 5.91M | 6.20M | 3.62M | 1.76M | 3.71M | 1.91M | 1.63M |
| Free Cash Flow | -55.1M | -15.0M | -178M | -139M | -118M | -150M | -90.6M | -80.0M | -72.1M | -83.0M | -112M |
| Ratios | |||||||||||
| ROE | -21.8% | -6.6% | -70.6% | -65.8% | -39.8% | -79.7% | -84.5% | -5.9% | -57.7% | -134.2% | -197.9% |
| ROA | -18.8% | -5.2% | -51.6% | -48.6% | -31.1% | -56.9% | -41.5% | -3.0% | -25.6% | -29.1% | -15.6% |
| Net Profit Margin | -67.6% | -12.6% | -285.2% | -244.8% | -120.5% | -252.3% | -79.0% | -15.8% | -45.1% | -49.9% | -51.7% |
| Debt to Equity | 0.01x | 0.00x | - | 0.13x | 0.10x | 0.11x | 0.25x | 0.22x | 0.32x | 1.92x | 1.39x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MacroGenics Inc dividends
MacroGenics Inc has not paid dividends in the last 9 fiscal years.
Who owns MacroGenics Inc
- Insiders 3.61%
- Institutions 79.00%
- Public & others 17.39%
- Shares outstanding 63.9M
- Free float 56.6M
Top funds holding MGNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.93M | 3.01% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.53M | 2.39% | 0.00% | Oct 2026 |
| Canada Life US Small-Mid Cap Growth F | 903K | 1.41% | 0.00% | Aug 2026 |
| Wasatch Micro Cap | 771K | 1.21% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 683K | 1.07% | 0.00% | Aug 2026 |
| PPF Helix Biotechnology I USD | 629K | 0.99% | +43.18% | Jul 2026 |
| iShares Russell 2000 Growth ETF | 519K | 0.81% | -0.38% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 487K | 0.76% | -7.82% | Sep 2026 |
| Vanguard Explorer Inv | 422K | 0.66% | 0.00% | Sep 2026 |
| Nomura Healthcare Fund Class I | 420K | 0.66% | 0.00% | Sep 2026 |
| Vanguard VIF Small Co Gr | 388K | 0.61% | -11.45% | Sep 2026 |
| Wasatch Ultra Growth | 373K | 0.58% | -66.66% | Sep 2026 |
| Vanguard Russell 2000 ETF | 366K | 0.57% | +1.15% | Sep 2026 |
| Fidelity Enhanced Small Cap Core ETF | 326K | 0.51% | +0.27% | Oct 2026 |
| Fidelity Extended Market Index | 290K | 0.45% | +1.70% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 257K | 0.40% | 0.00% | Sep 2026 |
| Mackenzie GQE US Small Cap F8 | 202K | 0.32% | 0.00% | Aug 2026 |
| iShares Micro-Cap ETF | 192K | 0.30% | 0.00% | Oct 2026 |
| IG Mackenzie GQE U.S. Sm Md Cap Eq C NL | 173K | 0.27% | 0.00% | Aug 2026 |
| Fidelity® SAI Small-Mid Cap Momt Idx | 173K | 0.27% | -3.93% | Sep 2026 |
Top institutions holding MGNX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 5.01M | 7.84% | -16.72% | Jun 2026 |
| BlackRock Inc | 4.68M | 7.33% | +302.29% | Jun 2026 |
| Vanguard Capital Management, LLC | 2.66M | 4.16% | +0.08% | Jun 2026 |
| Acadian Asset Management LLC | 2.54M | 3.98% | -0.01% | Sep 2026 |
| Bank of America Corp | 2.49M | 3.90% | +3.60% | Jun 2026 |
| Two Sigma Investments LLC | 2.47M | 3.86% | -2.46% | Jun 2026 |
| Millennium Management LLC | 2.37M | 3.72% | -15.03% | Jun 2026 |
| Renaissance Technologies Corp | 2.18M | 3.41% | -17.22% | Sep 2026 |
| Wasatch Advisors LP | 2.02M | 3.16% | +29.44% | Jun 2026 |
| RA Capital Management, LLC | 1.86M | 2.92% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.82M | 2.85% | +50.58% | Jun 2026 |
| Mackenzie Investments | 1.64M | 2.57% | +174.94% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.62M | 2.53% | -20.21% | Jun 2026 |
| Geode Capital Management, LLC | 1.58M | 2.47% | +126.09% | Jun 2026 |
| Affinity Asset Advisors, LLC | 1.22M | 1.90% | +143.32% | Jun 2026 |
| D. E. Shaw & Co LP | 1.06M | 1.66% | +0.43% | Jun 2026 |
| Jacobs Levy Equity Management, Inc. | 1.00M | 1.57% | +127.20% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 1.00M | 1.57% | +15.35% | Jun 2026 |
| State Street Corp | 864K | 1.35% | +194.08% | Jun 2026 |
| The Goldman Sachs Group Inc | 558K | 0.87% | +104.04% | Jun 2026 |
MacroGenics Inc company profile
- Company name
- MacroGenics Inc
- Ticker
- MGNX.US
- Exchange
- USA Stocks
- Listed since
- Oct 10, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 293
- Fiscal year end
- December
- Address
- 9704 Medical Center Drive, Rockville, MD, United States, 20850
- Phone
- 301 251 5172
- Website
- macrogenics.com
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
MacroGenics Inc management
9- Mr. Eric Blasius RisserCEO, President & Director · born 1973
- Mr. James KarrelsSenior VP & CFO · born 1967
- Dr. Ezio Bonvini M.D.Senior VP of Research & Chief Scientific Officer · born 1954
- Dr. Araba Lamouse-Smith Ph.D.Vice President of Technical Operations
- Mr. Jeffrey Stuart Peters J.D.Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer · born 1971
- Mr. Steve HarigSenior Vice President of Human Resources
- Mr. Harish KrishnaswamySenior Vice President of Business Development & Portfolio Planning
- Dr. Frank George Perabo FEBU, M.D., Ph.D.Vice President & Interim Head of Clinical Development · born 1964
- Ms. Beth SmithVP, Controller & Treasurer · born 1968